Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 1.00 |
| ▸ | ITGAV | P06756 | 20/20 | 1.00 |
| ▸ | ITGB5 | P18084 | 6/20 | 1.00 |
| ▸ | ITGB6 | P18564 | 6/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7262407 | 0.93 | ITGB3 (0.86) | ITGB3ITGAVITGB5ITGB6ITGA2B | |
| SCHEMBL7267221 | 0.93 | ITGB3 (0.86) | ITGB3ITGAVITGB5ITGB6ITGA2B | |
| SCHEMBL7104922 | 0.89 | ITGB3 (0.89) | ITGB3ITGAVITGB5ITGB6ITGA2B | |
| SCHEMBL7261880 | 0.87 | ITGB3 (0.81) | ITGB3ITGAVITGB5ITGB6ITGA2B | |
| SCHEMBL7261887 | 0.87 | ITGB3 (0.81) | ITGB3ITGAVITGB5ITGB6ITGA2B | |
| SCHEMBL12259087 | 0.86 | ITGAV (1.00) | ITGB3ITGAVITGB5ITGB6ITGA2B | |
| SCHEMBL7262439 | 0.86 | ITGAV (1.00) | ITGB3ITGAVITGB5ITGB6ITGA2B | |
| SCHEMBL7263127 | 0.85 | ITGB3 (0.79) | ITGB3ITGAVITGB5ITGB6ITGA2B | |
| SCHEMBL7105700 | 0.83 | ITGB3 (0.94) | ITGB3ITGAVITGB5ITGB6ITGA2B | |
| SCHEMBL13109235 | 0.82 | ITGAV (0.77) | ITGB3ITGAVITGB5ITGB6ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20180193270-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9453222-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150191726-A1 | LIGAND-CONJUGATED MONOMERS | BANK OF AMERICA, N.A. | 2015-07-09 | — | — | US | disclosed |
| US-8957223-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130184328-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8404862-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404862-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8017763-B2 | Chemically modified oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017763-B2 | Chemically modified oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-7815908-B2 | Methods and compositions for treating and preventing disease associated with αVβ5 integrin | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090280118-A1 | antibody that binds the same epitope of alpha v beta 5 as bound by ALULA ; Pulmonary edema | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090280118-A1 | antibody that binds the same epitope of alpha v beta 5 as bound by ALULA ; Pulmonary edema | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-11-12 | — | — | US | disclosed |
| US-7582744-B2 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582744-B2 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-6649613-B1 | Integrin inhibitors | MERCK PATENT GMBH (DE) | 2003-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280118-A1 | antibody that binds the same epitope of alpha v beta 5 as bound by ALULA ; Pulmonary edema | ITGA5, ITGAV, ITGB5 | ITGB3 12/4885ITGAV 2/4885ITGB5 3/4885 |
| US-20180193270-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | ITGB3 1717/4885ITGAV 799/4885ITGB5 629/4885 |
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | NSUN2, RNGTT, DCLRE1B | ITGB3 829/4885ITGAV 955/4885ITGB5 469/4885 |
| US-20130184328-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | ITGB3 174/4885ITGAV 384/4885ITGB5 247/4885 |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | ITGB3 1717/4885ITGAV 799/4885ITGB5 629/4885 |
| US-20150191726-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | ITGB3 174/4885ITGAV 384/4885ITGB5 247/4885 |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | ITGB3 174/4885ITGAV 384/4885ITGB5 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.